Moderate hypofractionation for prostate cancer.


Journal Article (Review)

The biologic effects of changing the daily radiation dose (fractionation) have been studied for more than a century. The fractionation question in the treatment of prostate cancer came into stark relief in 1999 with the publication of a provocative report suggesting that hypofractionated regimens could maintain the therapeutic ratio with logistic and financial advantages. In the last two decades medical evidence, weak and strong, has accumulated on the efficacy and toxicity of hypofractionated regimens in the radiotherapeutic treatment of prostate cancer. This brief review will focus on the results of randomized trials that compare moderate hypofractionation (HF) to conventional fractionation (CF). Extreme HF is covered in a separate review within this issue.

Full Text

Duke Authors

Cited Authors

  • Lee, WR; Koontz, BF

Published Date

  • June 2018

Published In

Volume / Issue

  • 7 / 3

Start / End Page

  • 321 - 329

PubMed ID

  • 30050793

Pubmed Central ID

  • 30050793

International Standard Serial Number (ISSN)

  • 2223-4691

Digital Object Identifier (DOI)

  • 10.21037/tau.2017.12.07


  • eng

Conference Location

  • China